Source comparison
Difference Between GHK-Cu and TB-500: Research Comparison
This table compares the core characteristics that differentiate GHK-Cu from TB-500 in research settings: Primary Mechanism Copper-dependent gene expression modulation; upregulates collagen synthesis, MMPs, growth factors Actin-binding and sequestration; promot
This comparison does not assign a generated winner or score.
- This table compares the core characteristics that differentiate GHK-Cu from TB-500 in research settings:
- Primary Mechanism
- Copper-dependent gene expression modulation; upregulates collagen synthesis, MMPs, growth factors
- Actin-binding and sequestration; promotes cell migration, angiogenesis via cytoskeletal regulation
- Distinct pathways—GHK-Cu works through transcriptional changes, TB-500 through structural protein dynamics
- Molecular Weight
- ~340 Da (tripeptide + Cu²⁺)
- ~4,963 Da (43 amino acids)
- Size affects tissue penetration—GHK-Cu diffuses more readily through extracellular matrix
- Half-Life (estimated)
- 30–90 minutes in serum; copper binding extends activity
- ~10 days (extrapolated from thymosin beta-4 studies in humans)
- TB-500's longer half-life reduces dosing frequency in protocols but may complicate washout
- Optimal Dosing Context
- Continuous low-dose exposure (mimics physiological levels); topical or frequent subcutaneous
- Bolus dosing with weekly intervals; systemic administration preferred
- GHK-Cu suits daily protocols; TB-500 fits intermittent intervention studies
- Primary Research Focus
- Dermal wound healing, photoaging, hair growth, neuroprotection
- Cardiovascular repair, tendon healing, muscle injury, stroke recovery
- Evidence depth varies—GHK-Cu has more human dermal data; TB-500 has more cardiovascular animal models
- Regulatory Status
- Unrestricted for research; available in cosmetic formulations
- WADA-prohibited; research-only access; veterinary use documented
- Affects commercial development—GHK-Cu has clearer path to consumer products
- Common Concentration Range
- 1–10 nM in vitro (optimal ~1 nM); 0.05–3% in topical formulations
- 2–10 mg/kg in animal models; human equivalent ~0.3–1.5 mg/kg
- Concentration-response curves differ—GHK-Cu shows hormetic effect (reduced activity at high doses)